Abstract:Background: Lymph node metastasis (LNM) is an independent prognostic factor in numerous types of cancer. Therefore, a LNM-related gene-based nomogram may precisely predict survival and drug sensitivity, and reveal the mechanism underlying LNM. Materials and Methods: Gene sequencing profiles of pan-cancer data (33 cancer types) were acquired from The Cancer Genome Atlas UCSC Xena database. Patients were classified into primary (N = 10,071) and testing (N = 5,036) cohorts. The lymph node score (LNscore) was established via single-cell RNA sequencing, whole-transcriptome sequencing, machine learning, and Cox regression analyses. A novel prognosis model, formulated by incorporating the LNscore and clinical characteristics, was evaluated using the concordance index, calibration curve, and decision curve analysis. Moreover, patients were assigned into high- and low-risk groups according to the median LNscore. We investigated these two groups for survival prognosis, functional enrichment, immune infiltration, and drug sensitivity. In addition, we silenced and overexpressed insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2). We also analyzed the behavior of breast cancer (BRCA) cells regarding lymphatic metastasis and lymphangiogenesis in vitro . IGF2BP2 stimulated the proliferation of BRCA cells via 5-Ethynyl-2’-deoxyuridine and Cell Counting Kit-8 experiments. Results: A LNM-related set of 12 genes was identified and utilized to determine the LNscore. The concordance-index of both cohorts in the LNscore-based model was >0.7. The immune landscape revealed that the sensitivity to immunotherapy might be better in the high-risk group versus the low-risk group. In addition, we discovered that IGF2BP2 was overexpressed in BRCA tissues and significantly associated with poor survival. Functional analysis indicated that IGF2BP2 promoted BRCA cell migration and proliferation. Additionally, IGF2BP2 accelerated lymphatic metastasis and lymphangiogenesis in vivo . Conclusions: A novel LNscore-based model was established via comprehensive analysis of LNM-related genes. This model can accurately predict patient survival and drug sensitivity, and reveal the mechanism of LNM in the pan-cancer setting.

Compound Signature Detection on LINCS L1000 Big Data

An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer

Systematically Studying Kinase Inhibitor Induced Signaling Network Signatures by Integrating Both Therapeutic and Side Effects.

Integrating Genomics and Proteomics Data to Predict Drug Effects Using Binary Linear Programming

A Comprehensive Evaluation of Connectivity Methods for L1000 Data.

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine

Comprehensive and Computable Molecular Diagnostic Panel (c2dx) from Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer from Fine Needle Aspirates

Metastasis-related Gene Identification by Compound Constrained NMF and a Semisupervised Cluster Approach Using Pancancer Multiomics Features.

Predicting Drug Response of Small Cell Lung Cancer Cell Lines Based on Enrichment Analysis of Complex Gene Signatures

Systematic Identification of Non-Coding Pharmacogenomic Landscape in Cancer

CDS-DB, an omnibus for patient-derived gene expression signatures induced by cancer treatment

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data

Drug Target Prediction Through Deep Learning Functional Representation of Gene Signatures

Single-cell and whole-transcriptome sequencing of lymph node metastasis-related gene signature: A large-scale pan-cancer cohort, machine learning and experimental study

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Ontological Representation, Integration, and Analysis of LINCS Cell Line Cells and Their Cellular Responses.

Integrative Serum Metabolic Fingerprints Based Multi‐Modal Platforms for Lung Adenocarcinoma Early Detection and Pulmonary Nodule Classification

Drug combination prediction for cancer treatment using disease-specific drug response profiles and single-cell transcriptional signatures

A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer

Deep-Learning Algorithm and Concomitant Biomarker Identification for NSCLC Prediction Using Multi-Omics Data Integration